|
Q3 FY2026
As of Sep 30, 2026
|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||||||
| Investments at fair value | |||||||||||||||||
| Non-controlled/non-affiliate investments | |||||||||||||||||
| Non-controlled/affiliate investments | |||||||||||||||||
| Controlled affiliate investments | |||||||||||||||||
| Total investments at fair value | |||||||||||||||||
| Cash and cash equivalents | |||||||||||||||||
| Foreign cash (cost of $2,309 and $2,477, respectively) | |||||||||||||||||
| Restricted cash and cash equivalents | |||||||||||||||||
| Collateral on derivatives | |||||||||||||||||
| Deferred financing costs | |||||||||||||||||
| Interest receivable on investments | |||||||||||||||||
| Interest rate swap | |||||||||||||||||
| Receivable for sales and paydowns of investments | |||||||||||||||||
| Prepaid insurance | |||||||||||||||||
| Unrealized appreciation on forward currency exchange contracts | |||||||||||||||||
| Dividend receivable | |||||||||||||||||
| Total Assets | |||||||||||||||||
| Liabilities | |||||||||||||||||
| Debt (net of unamortized debt issuance costs of $14,714 and $10,110, respectively) | |||||||||||||||||
| Interest rate swap | |||||||||||||||||
| Interest payable | |||||||||||||||||
| Payable for investments purchased | |||||||||||||||||
| Collateral payable on derivatives | |||||||||||||||||
| Unrealized depreciation on forward currency exchange contracts | |||||||||||||||||
| Base management fee payable | |||||||||||||||||
| Incentive fee payable | |||||||||||||||||
| Accounts payable and accrued expenses | |||||||||||||||||
| Distributions payable | |||||||||||||||||
| Total liabilities | |||||||||||||||||
| Net Assets | |||||||||||||||||
| Common stock, par value $0.001 per share, 100,000,000,000 and 100,000,000,000 shares authorized, 64,868,507 and 64,868,507 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively | |||||||||||||||||
| Paid in capital in excess of par value | |||||||||||||||||
| Total distributable loss | |||||||||||||||||
| Total Net Assets | |||||||||||||||||
| Total Liabilities and Total Net Assets | |||||||||||||||||
| Net asset value per share | |||||||||||||||||
Loading...